About US
Contact us
-
AstraZeneca to shell out £12M in severance dispute with workers at former England plantWhen AstraZeneca sold its Avlon, England plant to CDMO Avara in 2016, it was touted as a lifeline for the drugmaker’s 210 on-site employees who faced termination. Three years later, with the plant ba2019/7/22
-
Still on a cash-raising spree, Takeda shops €1.5B European drug sale: reportTakeda’s ax is about to fall again, this time on some over-the-counter and off-patent prescription drugs in Western Europe. The Japanese pharma, still working to pay down debt it incurred for its Shi2019/7/19
-
Novartis, aiming to clean up its rep, sets aside $700M for kickback settlementWith nearly decade-old bribery charges hanging over its head, Novartis has been eager to wriggle out of U.S. prosecutors’ crosshairs. Now, a settlement in the case appears to be in the works—and it c2019/7/19
-
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEOGene therapy Zolgensma is under the spotlight as Novartis launches what’s known as the world’s most expensive drug. And now, its chief has offered an early glimpse into the rollout. The Zolgensma lau2019/7/18
-
FDA investigators discover key Strides Pharma quality records in shredding roomFDA investigators, particularly in India, have learned it is best to look beyond the production floor, clean rooms and quality control labs when doing inspections. They look around shredders, in tras2019/7/18
-
Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing in breast cancerIn breast cancer, Novartis’ Kisqali is trailing closely behind Eli Lilly’s direct competitor Verzenio. Now it's gained even footing with its rival in England, at least where the country's cost-effect2019/7/17
-
3 drugmakers dominated opioid supplies as 76B pills flooded the U.S.: reportAs the nation’s opioid epidemic spiraled out of control at the turn of the decade, parts of rural America seemed awash in prescription drugs. But the extent to which drug distributors and manufacture2019/7/17
-
Seattle Genetics investors breathe a sigh of relief as Adcetris posts 30% sales growthIfSeattle Genetics'second-quarter earnings report is any indication, the company's lead product is finally living up to its potential. The companyunveiledthat sales of cancer drug Adcetris jumped 30%2019/7/16
-
Earnings bulletin: Johnson & Johnson's second quarter of 2019Johnson & Johnson kicked off the second-quarter earnings season Tuesday, reporting that its pharma unitoutperformedstruggling consumer healthcare and medical device segments. Pharma posted sales2019/7/16
-
Thanks to patent win, Amgen ready to kick PCSK9 rivals Sanofi, Regeneron off the market in GermanyAmgen and its PCSK9 rivals Sanofi and Regeneron have been battling over U.S. patents for years, but this week Amgen scored a win in Germany—and it's the sort of win the company would like to duplic2019/7/15